A growing body of evidence suggests that uterine artery embolization (UAE) is a viable alternative to surgery for symptomatic fibroids for women who don't desire future pregnancy. For many women, avoiding surgery is a tremendous relief. However, there are still unanswered questions about the safety and efficacy of UAE. This story reports on a randomized controlled trial published in this week's New England Journal of Medicine comparing UAE to surgery for symptomatic fibroids. This story does a good job of explaining the problem of fibroids, describing the treaments compared and why UAE is an important advancement. However, this story is limited by the lack of balance in its sources and leaving out important information on the costs and availability of the procedure.
The story accurately describes the prevalence and symptoms of uterine fibroids. The story provides adequate quantification of some of the most important things for consumers to know, such as the fact that after a year, there were no differences in the quality of life of the women assigned to UAE compared to those assigned to surgery and that 13% of those who underwent UAE had a repeat hospitalization, mostly for surgical intervention because of failure of UAE to achieve the desired results. The story could have provided more quantification of other pieces of information that women would want to know, such as length of hospital stay, time to return to work, or risk of serious adverse events.
The story implies that UAE is a new procedure. The story could have mentioned that the procedure has been performed for more than 10 years in Europe and the US. The story does mention some of the potential harms of UAE, such as the need for repeat procedures for treatment of recurrent symptoms and the fact that there are questions about safety of pregnancy after the procedure. The story should have also mentioned the potential for ovarian failure, causing infertility, infection, delayed complications and a small risk of emergency hysterectomy.
However, the story does not state whether uterine artery embolization (UAE) is available and if so, how widely. And availability is a real issue. It requires expertise in interventional vascular radiology and an interest in the female pelvic anatomy. Facilities offering the procedure would need strong links between gynecologists and radiologists to provide coordinated assessment and care. This is not explained in the piece. The story also does not describe the costs of UAE and how they compare to costs of surgery. The cost of UAE is quite high and for some women may not be covered by insurance.
The story does not describe the costs of uterine artery embolization or how they compare to costs of surgery. The cost of UAE is quite high and for some women may not be covered by insurance.
The story provides adequate quantification of some of the most important things for consumers to know, such as the fact that after a year, there were no differences in the quality of life of the women assigned to uterine artery embolization compared to those assigned to surgery and that 13% of those who underwent UAE had a repeat hospitalization, mostly for surgical intervention because of failure of UAE to achieve the desired results. The story could have provided more quantification of other pieces of information that women would want to know, such as length of hospital stay, time to return to work, or risk of serious adverse events.
The story does mention some of the potential harms of uterine artery embolization, such as the need for repeat procedures for treatment of recurrent symptoms and the fact that there are questions about safety of pregnancy after the procedure. The story should have also mentioned the potential for ovarian failure, causing infertility, infection, delayed complications and a small risk of emergency hysterectomy.
The story adequately describes the design of the current study.
The story accurately describes the prevalence and symptoms of uterine fibroids.
The story only uses quotes from the original article and accompanying editorial. It doesn't appear that the authors were even interviewed. The story should have quoted other clinicians/researchers who were not related to the study who could have provided some perspective on what this new information means for clinical practice.
The story does mention alternative options such as myomectomy (surgical removal of the fibroids), hysterectomy (surgical removal of the uterus) in addition to uterine artery embolization. The story could have mentioned other treatments such as watchful waiting, pain medications or birth control pills.
The story does not state whether uterine artery embolization (UAE) is available and if so, how widely. And availability is a real issue. It requires expertise in interventional vascular radiology and an interest in the female pelvic anatomy. Facilities offering the procedure would need strong links between gynecologists and radiologists to provide coordinated assessment and care. This is not explained in the piece.
The story implies that uterine artery embolization is a new procedure. The story could have mentioned that the procedure has been performed for more than 10 years in Europe and the US, although it has been limited to mostly academic hospitals.
There is no way to know if the story relied on a press release as the sole source of information, although it is noteworthy that the story only uses quotes lifted from the published study and from an accompanying editorial. It doesn't appear that these people were actually interviewed.
Systematic, Criteria-Driven
Like Michael Corleone of science reporting that @garyschwitzer is (he tries to get out, bullshit disguised as #science #journalism keeps pulling him back in!), he drops this on @nytimes idiocy 🙄 in reporting T1 diabetes "cure"
HT @HealthNewsRevu
https://www.healthnewsreview.org/2021/11/cure-for-type-1-diabetes-weve-been-down-this-road-before-with-ny-times/
A great read on this weekend’s NYT claims of a cure for Type 1.
Cure for Type 1 diabetes? We’ve been down this road before with NY Times https://www.healthnewsreview.org/2021/11/cure-for-type-1-diabetes-weve-been-down-this-road-before-with-ny-times/
"But it is the framing and the emphasis of the #journalism by a leading science journalist at a leading newspaper that demands scrutiny. It has an impact on readers and on sick people that may cause harm by promoting false hope about extremely preliminary research"
👍👏💪 truth https://twitter.com/garyschwitzer/status/1465399358137024518
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like